S-1: Quoin Pharmaceuticals Eyes $21 Million in New Offering to Advance Rare Disease Pipeline

Quoin Pharmaceuticals is launching a public offering of ADSs and warrants, aiming to raise up to $21 million to further its research and development efforts in rare skin diseases.

Summary

• Quoin Pharmaceuticals is planning a public offering consisting of American Depositary Shares (ADSs), pre-funded warrants, Series D warrants, and Series E warrants.
• The company aims to raise up to $21 million through this offering.
• The funds are intended for general corporate purposes, including research and development, clinical testing, working capital, and potential acquisitions.
• The offering includes up to 2,089,552 ADSs, pre-funded warrants for the same amount, and Series D and E warrants also for up to 2,089,552 ADSs each.
• The assumed offering price is $3.35 per ADS and accompanying warrants, but the final price will be negotiated.
• The Series D warrants will expire two years from issuance, while the Series E warrants will expire in five years.
• A.G.P./Alliance Global Partners is acting as the exclusive placement agent for the offering.
• The offering is expected to terminate on February 28, 2024, unless fully subscribed or terminated earlier.
• The company has also entered into a Purchase Agreement with Alumni Capital LP, allowing them to sell up to $8,000,000 of newly issued ordinary shares represented by ADSs to Alumni, subject to certain conditions and limitations.

Sentiment

Score: 6

Explanation: The sentiment is neutral to slightly positive. While the company is raising capital, which is generally a positive sign for growth, there are also inherent risks associated with the company's financial position and the development of its product candidates.

Positives

• The offering will provide additional capital to advance Quoin Pharmaceuticals' research and development programs.
• The company has multiple pipeline products targeting rare skin diseases.
• The company has established marketing partnerships for QRX003 that cover 61 different countries.
• The company has a clear path forward for the development of QRX003 as a potential treatment for NS.

Negatives

• The company has a limited operating history and has incurred significant losses since its inception.
• The company has never generated any revenue from product sales or any other sources since inception, and may never be profitable.
• The company will need to raise additional funding to fund its working capital needs or consummate potential future acquisitions.
• There is no public market for the Pre-Funded Warrants or the Warrants being offered in this offering.

Risks

• Resales of the company's ADSs in the public market by shareholders as a result of this offering may cause the market price of the company's ADSs to fall.
• This offering may cause the trading price of the company's ADSs to decrease.
• You will experience immediate and substantial dilution in the net tangible book value per share of the ADSs you purchase.
• The company's management will have broad discretion over the use of the net proceeds from this offering, you may not agree with how the company uses the proceeds, and the proceeds may not be invested successfully.
• This is a reasonable best efforts offering, in which no minimum number or dollar amount of securities is required to be sold, and the company may not raise the amount of capital it believes is required for its business plans.
• The company may be unable to comply with the applicable continued listing requirements of Nasdaq.
• The market price for the company's ADSs may be volatile.

Future Outlook

The company intends to use the net proceeds from the sale of the securities under this prospectus for general corporate purposes, which may include operating expenses, research and development, including clinical and pre-clinical testing of our product candidates, working capital, future acquisitions and general capital expenditures.

Industry Context

The announcement reflects a common strategy for clinical-stage pharmaceutical companies to raise capital to fund ongoing research and development. The focus on rare and orphan diseases aligns with a growing trend in the pharmaceutical industry, driven by regulatory incentives and unmet medical needs.

Comparison to Industry Standards

• Comparable companies raising capital in the biotech sector include Krystal Biotech, Inc., which is also developing treatments for rare diseases.
• The terms of the offering, including the use of ADSs and warrants, are typical for small-cap biotech companies seeking funding.
• The focus on rare diseases is similar to companies like BioMarin Pharmaceutical Inc. and Alexion Pharmaceuticals, which have successfully developed and commercialized orphan drugs.

Related Party Transactions

• In 2021, Quoin Inc. paid $100,000 of consulting expenses to a company controlled by Dennis Langer, a director.
• Approximately $8,000 and $48,000 and $12,000 were paid in 2021, 2022, and 2023, respectively, to Dr. Myers' son, who consulted on research and development matters.
• Due to limited funding, compensation due to Dr. Myers and Ms. Carter was accrued as indebtedness, with repayments made following the Merger.
• ADSs were issued to 2020 Noteholders, including directors, upon conversion of promissory notes.
• The exercise price of warrants held by the 2020 Noteholders was reduced to $0.00 as of July 14, 2022, and a total of 2,449 ADSs were issued to such noteholders.

Stakeholder Impact

• Shareholders may experience dilution as a result of the offering.
• Employees may benefit from increased funding for research and development.
• Patients with rare skin diseases may benefit from the development of new treatments.
• Suppliers and creditors may benefit from the company's increased financial stability.

Next Steps

• Complete the public offering of ADSs and warrants.
• Advance clinical trials for QRX003 and other product candidates.
• Seek regulatory approvals from the FDA and other agencies.
• Establish a sales and marketing infrastructure for commercializing approved products.
• Pursue business development activities to expand the pipeline.

Key Dates

Keywords

Quoin Pharmaceuticals, public offering, ADSs, warrants, rare diseases, clinical trials, QRX003, Netherton Syndrome, A.G.P., Alliance Global Partners, Alumni Capital LP, capital raise